Pivotal readout

Amgen's dazodalibep cuts Sjogren's disease activity in phase 3 OASIZ-301

Both dosing schedules of dazodalibep beat placebo on systemic disease activity at week 48 in the 648-patient OASIZ-301 trial. The 1,500 mg monthly regimen also eased patient-reported dryness. Amgen will show full data at ACR Convergence 2026 and has further phase 3 and extension studies running.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call